As PRT543 was generally well tolerated by patients with recurrent/metastatic ACC [45], the anti-tumor activity of PRMT5 inhibitors may be further enhanced when given in combination with other therapeutic agents. The gene discussed is PRMT5; the disease is neoplasm.